AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10521108 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified FSH (75 IU FSH, <1 IU LH) for > or = 50 days before oocyte retrieval
Number of subjects: 78
Study 10521108 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 78
Study 8720265 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic synovectomy
Number of subjects: 58
Study 8720265 — intervention group
Group type: COMPARATOR
Intervention: Open synovectomy
Number of subjects: 58
Study 1775606 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion testing (TFD)
Number of subjects: 115
Study 7006882 — intervention group
Group type: COMPARATOR
Intervention: Sublingual nitroglycerin
Number of subjects: 15
Study 7006882 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrityl tetranitrate (ETN) - all forms
Number of subjects: 15
Study 7006882 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ETN
Number of subjects: 15
Study 31481605 — intervention group
Group type: EXPERIMENTAL
Intervention: AsthmaTuner
Number of subjects: 77
Study 31481605 — intervention group
Group type: EXPERIMENTAL
Intervention: AsthmaTuner (used once a week or more)
Number of subjects: 77
Study 31481605 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 77
Study 28001305 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid video with culturally tailored information about colorectal cancer screening
Number of subjects: 89
Study 28001305 — intervention group
Group type: COMPARATOR
Intervention: Attention control video about hypertension
Number of subjects: 89
Study 28001305 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study 26489054 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 46
Study 26489054 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 46
Study 26489054 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 22926481 — intervention group
Group type: EXPERIMENTAL
Intervention: Malic acid 1%
Number of subjects: 45
Study 22926481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 21116652 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Number of subjects: 45
Study 21116652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 19412512 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring system for malignancy prediction based on TRUS findings
Number of subjects: 350
Study 19412512 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUS findings (shape, margin irregularity, vascularity)
Number of subjects: 350
Study 19412512 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analysis
Number of subjects: 350
Study 17070593 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser for LASIK
Number of subjects: 100
Study 17070593 — intervention group
Group type: COMPARATOR
Intervention: Mechanical microkeratome LASIK
Number of subjects: 100
Study 15001203 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 72
Study 15001203 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 72
Study 12370218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Bx VELOCITY stent (SES)
Number of subjects: 238
Study 12370218 — intervention group
Group type: COMPARATOR
Intervention: Bare metal Bx VELOCITY stent (BS)
Number of subjects: 238
Study 9847643 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose propofol (0.3 mg/kg plus 10 mg/kg/h perfusion)
Number of subjects: 40
Study 9847643 — intervention group
Group type: COMPARATOR
Intervention: Propofol with nitroprusside (8 mg/kg/h perfusion)
Number of subjects: 40
Study 9734496 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 3000 mg/day
Number of subjects: 650
Study 1884720 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120-360 mg/day
Number of subjects: 128
Study 1884720 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 50-200 mg/day
Number of subjects: 128
Study 6347922 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clindamycin
Number of subjects: 30
Study 6347922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30711602 — intervention group
Group type: EXPERIMENTAL
Intervention: Time pressure
Number of subjects: 40
Study 30711602 — intervention group
Group type: COMPARATOR
Intervention: No time pressure
Number of subjects: 40
Study 26908586 — intervention group
Group type: EXPERIMENTAL
Intervention: High perceived control and high preference for control
Number of subjects: 119
Study 26908586 — intervention group
Group type: COMPARATOR
Intervention: Low perceived control or low preference for control
Number of subjects: 119
Study 27040154 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnosine 2 g daily for 12 weeks
Number of subjects: 30
Study 27040154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24294984 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence promotion program
Number of subjects: 86
Study 23182488 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week course
Number of subjects: 37
Study 23182488 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week course
Number of subjects: 37
Study 23182488 — intervention group
Group type: COMPARATOR
Intervention: Baseline scores
Number of subjects: 37
Study 23182488 — intervention group
Group type: COMPARATOR
Intervention: Comparison of course lengths
Number of subjects: 37
Study 20740485 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-rTMS (90% of resting motor threshold, 5 Hz, 600 pulses-a-day for 10 days)
Number of subjects: 22
Study 20740485 — intervention group
Group type: COMPARATOR
Intervention: Sham-rTMS
Number of subjects: 22
Study 20740485 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-rTMS
Number of subjects: 22
Study 17436334 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 32
Study 17436334 — intervention group
Group type: COMPARATOR
Intervention: Piggyback method
Number of subjects: 32
Study 16011198 — intervention group
Group type: EXPERIMENTAL
Intervention: HIF-1alpha in proliferating phase
Number of subjects: 28
Study 16011198 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF in proliferating phase
Number of subjects: 28
Study 16011198 — intervention group
Group type: EXPERIMENTAL
Intervention: HIF-1alpha in involuting phase
Number of subjects: 28
Study 16011198 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF in involuting phase
Number of subjects: 28
Study 16011198 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvessel density (MVD) in proliferating phase
Number of subjects: 28
Study 16011198 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvessel density (MVD) in involuting phase
Number of subjects: 28
Study 16011198 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between HIF-1alpha and VEGF
Number of subjects: 28
Study 16011198 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between HIF-1alpha and MVD
Number of subjects: 28
Study 11931782 — intervention group
Group type: EXPERIMENTAL
Intervention: 165 microg/injection
Number of subjects: 150
Study 11931782 — intervention group
Group type: EXPERIMENTAL
Intervention: 330 microg/injection (less intense regimen)
Number of subjects: 150
Study 11931782 — intervention group
Group type: EXPERIMENTAL
Intervention: 330 microg/injection (more intense regimen)
Number of subjects: 150
Study 11931782 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with intravitreous fomivirsen
Number of subjects: 150
Study 9056060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (2000 mg twice daily for 5 days)
Number of subjects: 18
Study 8140694 — intervention group
Group type: EXPERIMENTAL
Intervention: CDI (Color Doppler Imaging) assessment of retrobulbar circulation
Number of subjects: 0
Study 8140694 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 0
Study 3527513 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam (0.25 mg or 0.5 mg)
Number of subjects: 63
Study 3527513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 3527513 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam to placebo switch
Number of subjects: 63
Study 30382860 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-free body-weight-supported treadmill training (BWSTT) without assistance from handrails or assistive devices
Number of subjects: 29
Study 30382860 — intervention group
Group type: COMPARATOR
Intervention: Hands-free body-weight-supported treadmill training (BWSTT) with challenging mobility skills
Number of subjects: 29
Study 30382860 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HF and HF + C)
Number of subjects: 29
Study 27735985 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration protocol at optimal frequency (WBV-OF) + Traditional rehabilitation programme (TRP)
Number of subjects: 34
Study 27735985 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation programme (TRP)
Number of subjects: 34
Study 25577914 — intervention group
Group type: EXPERIMENTAL
Intervention: Baimai ointment, fomentation, functional exercises
Number of subjects: 43
Study 25577914 — intervention group
Group type: COMPARATOR
Intervention: Placebo, fomentation, functional exercises
Number of subjects: 43
Study 23186965 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine-QR (1.6 to 4.8 mg/day)
Number of subjects: 515
Study 23186965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 515
Study 21189853 — intervention group
Group type: COMPARATOR
Intervention: labetalol (0.25 mg/kg)
Number of subjects: 75
Study 21189853 — intervention group
Group type: COMPARATOR
Intervention: esmolol (0.5 mg/kg)
Number of subjects: 75
Study 21189853 — intervention group
Group type: COMPARATOR
Intervention: control (10 ml 0.9% saline)
Number of subjects: 75
Study 18373383 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone-ER (20 to 80 mg/day, most patients received 60 or 80 mg/day by week 3)
Number of subjects: 0
Study 18373383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18373383 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone-ER
Number of subjects: 0
Study 15747682 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative dose of prophylactic antibiotic with no postoperative antibiotics
Number of subjects: 215
Study 15747682 — intervention group
Group type: COMPARATOR
Intervention: Preoperative dose of antibiotics with postoperative antibiotics for 7 days
Number of subjects: 215
Study 12767655 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma VBT
Number of subjects: 133
Study 12767655 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta VBT
Number of subjects: 133
Study 12767655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 12767655 — intervention group
Group type: EXPERIMENTAL
Intervention: True aorto-ostial lesions (Gamma VBT)
Number of subjects: 133
Study 12767655 — intervention group
Group type: EXPERIMENTAL
Intervention: True aorto-ostial lesions (Beta VBT)
Number of subjects: 133
Study 12767655 — intervention group
Group type: COMPARATOR
Intervention: True aorto-ostial lesions (Placebo)
Number of subjects: 133
Study 10498024 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous barriers derived from hyaluronic acid
Number of subjects: 0
Study 10498024 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier gels
Number of subjects: 0
Study 10498024 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine usage of adhesion prevention measures
Number of subjects: 0
Study 9019079 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 92
Study 1734795 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-stat strategy
Number of subjects: 20
Study 1734795 — intervention group
Group type: COMPARATOR
Intervention: pH-stat strategy
Number of subjects: 20
Study 6203313 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthralin 2% (Anthraderm)
Number of subjects: 72
Study 6203313 — intervention group
Group type: COMPARATOR
Intervention: Verucid (comparative drug)
Number of subjects: 72
Study 31740271 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 15
Study 31740271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30497620 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced training in providing constructive feedback
Number of subjects: 836
Study 30497620 — intervention group
Group type: COMPARATOR
Intervention: Untrained/signed group
Number of subjects: 836
Study 30497620 — intervention group
Group type: COMPARATOR
Intervention: Control activity
Number of subjects: 836
Study 30497620 — intervention group
Group type: EXPERIMENTAL
Intervention: Signature status (signed/unsigned)
Number of subjects: 836
Study 27558180 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted decolonization with chlorhexidine and mupirocin
Number of subjects: 3173
Study 27558180 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal decolonization without screening
Number of subjects: 3173
Study 27558180 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and isolation without decolonization
Number of subjects: 3173
Study 27558180 — intervention group
Group type: COMPARATOR
Intervention: Baseline period
Number of subjects: 3173
Study 27558180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention periods
Number of subjects: 3173
Study 27558180 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine susceptibility
Number of subjects: 3173
Study 27558180 — intervention group
Group type: EXPERIMENTAL
Intervention: qacA or qacB gene presence
Number of subjects: 3173
Study 24988179 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid treatment (1.9 g EPA and 1.5 g DHA)
Number of subjects: 41
Study 24988179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 23724240 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment plus immunotherapy
Number of subjects: 60
Study 23724240 — intervention group
Group type: COMPARATOR
Intervention: Topical treatment with steroids and/or tacrolimus (Control)
Number of subjects: 60
Study 19588187 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic bolus tracking (protocol 1)
Number of subjects: 79
Study 19588187 — intervention group
Group type: COMPARATOR
Intervention: Empiric scan delay (protocol 2)
Number of subjects: 79
Study 17369783 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy for neck pain
Number of subjects: 0
Study 17369783 — intervention group
Group type: COMPARATOR
Intervention: Control groups of chronic neck pain subjects
Number of subjects: 0
Study 15634731 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive transcranial direct current stimulation (tDCS)
Number of subjects: 0
Study 15634731 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 12112719 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based computer navigation
Number of subjects: 150
Study 12112719 — intervention group
Group type: COMPARATOR
Intervention: Free-hand method (after introduction of CAS)
Number of subjects: 150
Study 12112719 — intervention group
Group type: COMPARATOR
Intervention: Free-hand method (before introduction of CAS)
Number of subjects: 150
Study 9697880 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell disease
Number of subjects: 2090
Study 9697880 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pre-B (or null cell) disease
Number of subjects: 2090
Study 9697880 — intervention group
Group type: EXPERIMENTAL
Intervention: Common or pre-B disease
Number of subjects: 2090
Study 9697880 — intervention group
Group type: EXPERIMENTAL
Intervention: CD10-positive leukaemia
Number of subjects: 2090
Study 9697880 — intervention group
Group type: EXPERIMENTAL
Intervention: CD10-negative leukaemia
Number of subjects: 2090
Study 8538807 — intervention group
Group type: EXPERIMENTAL
Intervention: CareMap and nursing case management
Number of subjects: 0
Study 8538807 — intervention group
Group type: EXPERIMENTAL
Intervention: CareMap development by multidisciplinary team
Number of subjects: 0
Study 2172394 — intervention group
Group type: EXPERIMENTAL
Intervention: WC3 rotavirus vaccine
Number of subjects: 206
Study 2172394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 2172394 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous rotavirus infection, high levels of WC3 neutralizing antibody, maternal serotype 1 neutralizing antibody (titer >= 30)
Number of subjects: 206
Study 1020905 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental epidural analgesia
Number of subjects: 28
Study 1020905 — intervention group
Group type: COMPARATOR
Intervention: Control group (no epidural analgesia)
Number of subjects: 28
Study 1020905 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (epidural and control)
Number of subjects: 28
Study 30856158 — intervention group
Group type: EXPERIMENTAL
Intervention: Qbrexza (glycopyrronium cloth)
Number of subjects: 0
Study 25828260 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberative methods (4 different methods)
Number of subjects: 1774
Study 25828260 — intervention group
Group type: COMPARATOR
Intervention: Reading materials only (RMO)
Number of subjects: 1774
Study 22587973 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment combined with comprehensive rehabilitation therapy
Number of subjects: 124
Study 22587973 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive rehabilitation therapy only
Number of subjects: 124
Study 21086596 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave resonance therapy with 'fluctuating' frequency and varied wave range
Number of subjects: 0
Study 18489485 — intervention group
Group type: EXPERIMENTAL
Intervention: Injected non-setting calcium hydroxide (NS Ca(OH)(2)) dressing
Number of subjects: 150
Study 18489485 — intervention group
Group type: COMPARATOR
Intervention: Spirally filled non-setting calcium hydroxide (NS Ca(OH)(2)) dressing
Number of subjects: 150
Study 15890591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal amifostine (1,500 mg)
Number of subjects: 53
Study 15890591 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous amifostine (500 mg)
Number of subjects: 53
Study 12917182 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 51
Study 12917182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 10605192 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral agents
Number of subjects: 0
Study 10605192 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 8620521 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 300,000 IU human natural IL-2 (hnIL-2) per day for 2 weeks
Number of subjects: 0
Study 8620521 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 150,000 IU human natural IL-2 (hnIL-2) per day
Number of subjects: 0
Study 8620521 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 300,000 IU human natural IL-2 (hnIL-2) per day
Number of subjects: 0
Study 1682600 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based maternity-care programme with trained midwives attending home deliveries and managing obstetric complications.
Number of subjects: 0
Study 1682600 — intervention group
Group type: COMPARATOR
Intervention: Control area without midwives.
Number of subjects: 0
Study 6755208 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue treatment for 3 years
Number of subjects: 493
Study 6755208 — intervention group
Group type: COMPARATOR
Intervention: Stop treatment after 18 months or 2 years
Number of subjects: 493
Study 6755208 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue treatment for 2 years
Number of subjects: 493
Study 31303526 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein meal (41% of energy from protein, 29% from carbohydrates)
Number of subjects: 0
Study 31303526 — intervention group
Group type: COMPARATOR
Intervention: Standard meal (15% from protein, 46% from carbohydrate)
Number of subjects: 0
Study 31303526 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein meal
Number of subjects: 0
Study 29279062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy tablets
Number of subjects: 41
Study 29279062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy drops
Number of subjects: 41
Study 29279062 — intervention group
Group type: COMPARATOR
Intervention: Both tablets and drops
Number of subjects: 41
Study 27154364 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil supplementation at a dose of 60mg/Kg/day
Number of subjects: 15
Study 27154364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 24136296 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment
Number of subjects: 44
Study 24136296 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 44
Study 24136296 — intervention group
Group type: EXPERIMENTAL
Intervention: TB‐IRIS patients
Number of subjects: 44
Study 24136296 — intervention group
Group type: COMPARATOR
Intervention: Non-IRIS controls
Number of subjects: 44
Study 22490180 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning-preference participants tested in the morning
Number of subjects: 80
Study 22490180 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening-preference participants tested in the afternoon
Number of subjects: 80
Study 22490180 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants tested at their optimal times of day
Number of subjects: 80
Study 22490180 — intervention group
Group type: COMPARATOR
Intervention: Participants tested at their nonoptimal times of day
Number of subjects: 80
Study 20836788 — intervention group
Group type: EXPERIMENTAL
Intervention: Geiger counter screening
Number of subjects: 30
Study 20836788 — intervention group
Group type: COMPARATOR
Intervention: Portal radiation screening
Number of subjects: 30
Study 20836788 — intervention group
Group type: COMPARATOR
Intervention: Both devices
Number of subjects: 30
Study 18540923 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1,500 mg or 5 pills at bedtime for 6 weeks)
Number of subjects: 21
Study 18540923 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 21